Search
Glossary Site Map
Home

About Algeta


Algeta is an oncology company developing treatments for bone metastases and disseminated tumor types. The company's lead product Alpharadin is targeting bone metastases which occur frequently in major cancers including hormone-refractory prostate cancer, breast, lung, kidney and thyroid. The treatment of bone metastases represents an area of high unmet medical need.

Algeta's pipeline is built on world-leading, proprietary technology. Algeta is developing new, targeted cancer alpha-pharmaceuticals that harness the unique characteristics of alpha particle emitters to destroy cancer cells. Alpha particle emitters are potent, well tolerated and convenient to use.

Alpharadin has demonstrated an increase in overall patient survival, improved quality of life and a placebo-like safety profile in an extensive phase II clinical trial program for bone metastases in hormone-refractory prostate cancer. Alpharadin is now actively recruiting patients in more than 100 centres in a phase III study which began in mid 2008.

The highly promising clinical results achieved with Alpharadin to-date combined with its unique bone-targeting properties highlight the potential of this new generation of cancer therapeutics to be a first-choice treatment for bone metastases.

Alpharadin phase III trial

For further information including a video on the Alpharadin ALSYMPCA phase III trial, please press the logo above.